|
|||||
|
|
Acquired hemophilia A: a review of recent data and new therapeutic options |
|
| Authors: | Massimo Franchini Stefania Vaglio Giuseppe Marano Carlo Mengoli Sara Gentili Simonetta Pupella |
| Institution: | 1. Italian National Blood Centre, National Institute of Health, Rome, Italy;2. Department of Haematology and Transfusion Medicine, ‘Carlo Poma’ Hospital, Mantua, Italy;3. Department of Clinical and Molecular Medicine, ‘Sapienza’ University of Rome, Rome, Italy |
| Abstract: | Objectives: Acquired hemophilia A (AHA) is a rare, but potentially life-threatening, bleeding disorder caused by an autoantibody against factor VIII that interferes with its coagulant function. Methods: We performed a narrative review focusing on the diagnostic aspects of AHA and on the current treatment strategies with particular regard to new data and therapeutic developments. Results: The management of this severe hemorrhagic disorder is based on the control of bleeding with the use of bypassing agents and on the utilization of a variety of immunosuppressant agents with the goal of eliminating the autoantibody permanently. Conclusion: The optimal management of AHA should be multidisciplinary and requires a close collaboration between physicians from various specialties. |
| Keywords: | Acquired hemophilia A factor VIII bleeding eradication therapy |